 Wesley Nuffer
Concepts (145)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Community Pharmacy Services | 11 | 2025 | 46 | 4.530 |
Why?
| | Students, Pharmacy | 16 | 2026 | 95 | 4.370 |
Why?
| | Education, Pharmacy | 17 | 2026 | 119 | 4.090 |
Why?
| | Pharmacies | 6 | 2025 | 40 | 2.050 |
Why?
| | Medication Therapy Management | 4 | 2019 | 72 | 2.050 |
Why?
| | Problem-Based Learning | 5 | 2026 | 97 | 1.560 |
Why?
| | Pharmacists | 8 | 2025 | 240 | 1.330 |
Why?
| | Curriculum | 9 | 2023 | 1063 | 1.200 |
Why?
| | Pharmacy | 4 | 2023 | 30 | 1.190 |
Why?
| | Diabetes Mellitus | 4 | 2025 | 1076 | 1.160 |
Why?
| | Diabetes Mellitus, Type 2 | 8 | 2025 | 2573 | 1.050 |
Why?
| | Cinnamomum zeylanicum | 2 | 2024 | 2 | 1.020 |
Why?
| | Hypoglycemic Agents | 7 | 2025 | 1388 | 1.020 |
Why?
| | Anti-Obesity Agents | 3 | 2016 | 67 | 0.980 |
Why?
| | Pharmaceutical Services | 3 | 2023 | 76 | 0.870 |
Why?
| | Educational Measurement | 5 | 2020 | 325 | 0.850 |
Why?
| | Receptors, Glucagon | 2 | 2014 | 26 | 0.850 |
Why?
| | Cinnamomum aromaticum | 1 | 2024 | 1 | 0.830 |
Why?
| | Blood Glucose | 3 | 2024 | 2326 | 0.820 |
Why?
| | Plant Preparations | 1 | 2024 | 37 | 0.810 |
Why?
| | Program Development | 5 | 2026 | 368 | 0.780 |
Why?
| | Liraglutide | 3 | 2016 | 32 | 0.680 |
Why?
| | Glucagon-Like Peptide 1 | 3 | 2015 | 146 | 0.590 |
Why?
| | Models, Educational | 1 | 2018 | 89 | 0.530 |
Why?
| | Perception | 2 | 2017 | 376 | 0.500 |
Why?
| | Cardiovascular Diseases | 3 | 2025 | 2172 | 0.490 |
Why?
| | Program Evaluation | 7 | 2026 | 941 | 0.480 |
Why?
| | Drugs, Investigational | 1 | 2014 | 31 | 0.420 |
Why?
| | Rural Health Services | 2 | 2012 | 139 | 0.390 |
Why?
| | Writing | 2 | 2020 | 102 | 0.380 |
Why?
| | Hypoglycemia | 2 | 2014 | 479 | 0.380 |
Why?
| | Public Health | 2 | 2019 | 569 | 0.370 |
Why?
| | Obesity | 2 | 2016 | 3070 | 0.360 |
Why?
| | Humans | 37 | 2026 | 144667 | 0.360 |
Why?
| | User-Computer Interface | 1 | 2013 | 165 | 0.350 |
Why?
| | Colorado | 7 | 2020 | 4558 | 0.340 |
Why?
| | Clinical Competence | 2 | 2017 | 1237 | 0.330 |
Why?
| | Patient Care | 2 | 2025 | 118 | 0.330 |
Why?
| | Hyperglycemia | 1 | 2014 | 374 | 0.320 |
Why?
| | Teaching | 1 | 2013 | 237 | 0.320 |
Why?
| | Preceptorship | 4 | 2026 | 63 | 0.320 |
Why?
| | Ambulatory Care Facilities | 1 | 2012 | 267 | 0.300 |
Why?
| | Patient-Centered Care | 3 | 2025 | 545 | 0.290 |
Why?
| | Weight Loss | 5 | 2025 | 839 | 0.290 |
Why?
| | Schools, Pharmacy | 2 | 2025 | 48 | 0.250 |
Why?
| | Insulin | 2 | 2014 | 2502 | 0.250 |
Why?
| | Patient Care Team | 1 | 2012 | 690 | 0.240 |
Why?
| | Faculty, Pharmacy | 1 | 2026 | 20 | 0.230 |
Why?
| | Medically Underserved Area | 2 | 2020 | 100 | 0.230 |
Why?
| | Students | 2 | 2023 | 657 | 0.230 |
Why?
| | Professional-Patient Relations | 2 | 2018 | 154 | 0.210 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 2 | 2014 | 88 | 0.200 |
Why?
| | Mentors | 1 | 2026 | 214 | 0.200 |
Why?
| | Quality Improvement | 2 | 2023 | 1287 | 0.200 |
Why?
| | Bias | 1 | 2024 | 197 | 0.190 |
Why?
| | Osteoarthritis | 1 | 2025 | 196 | 0.180 |
Why?
| | Sugars | 1 | 2022 | 40 | 0.180 |
Why?
| | Phytotherapy | 1 | 2022 | 74 | 0.180 |
Why?
| | Body Weight | 2 | 2015 | 968 | 0.160 |
Why?
| | Clinical Trials, Phase III as Topic | 2 | 2022 | 116 | 0.160 |
Why?
| | Dietary Supplements | 1 | 2024 | 575 | 0.150 |
Why?
| | Trust | 1 | 2021 | 155 | 0.150 |
Why?
| | Professional Role | 2 | 2018 | 159 | 0.150 |
Why?
| | Cost Savings | 1 | 2019 | 85 | 0.150 |
Why?
| | Narration | 1 | 2020 | 78 | 0.140 |
Why?
| | Private Practice | 1 | 2018 | 17 | 0.140 |
Why?
| | Attitude of Health Personnel | 2 | 2020 | 1180 | 0.140 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2020 | 1406 | 0.130 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2014 | 3910 | 0.130 |
Why?
| | Canagliflozin | 1 | 2017 | 10 | 0.130 |
Why?
| | Glucosides | 1 | 2017 | 55 | 0.120 |
Why?
| | Managed Care Programs | 1 | 2017 | 140 | 0.120 |
Why?
| | Benzhydryl Compounds | 1 | 2017 | 81 | 0.120 |
Why?
| | Phentermine | 1 | 2016 | 14 | 0.120 |
Why?
| | Benzazepines | 1 | 2016 | 35 | 0.120 |
Why?
| | Bupropion | 1 | 2016 | 47 | 0.120 |
Why?
| | Health Occupations | 1 | 2015 | 36 | 0.110 |
Why?
| | Fructose | 1 | 2016 | 131 | 0.110 |
Why?
| | Disease Management | 1 | 2019 | 650 | 0.110 |
Why?
| | Drug Approval | 1 | 2015 | 91 | 0.110 |
Why?
| | Medication Adherence | 1 | 2019 | 540 | 0.110 |
Why?
| | Glucagon-Like Peptide-2 Receptor | 1 | 2014 | 16 | 0.110 |
Why?
| | United States Food and Drug Administration | 1 | 2015 | 205 | 0.110 |
Why?
| | Drug Combinations | 1 | 2016 | 393 | 0.110 |
Why?
| | Naltrexone | 1 | 2016 | 118 | 0.110 |
Why?
| | Rural Population | 1 | 2019 | 657 | 0.110 |
Why?
| | United States | 4 | 2025 | 16018 | 0.110 |
Why?
| | Immunoglobulin Fc Fragments | 1 | 2014 | 41 | 0.110 |
Why?
| | Injections, Subcutaneous | 1 | 2014 | 168 | 0.100 |
Why?
| | Accountable Care Organizations | 1 | 2013 | 10 | 0.100 |
Why?
| | Cough | 1 | 2014 | 123 | 0.100 |
Why?
| | Medicare | 1 | 2019 | 899 | 0.100 |
Why?
| | Chronic Disease | 1 | 2019 | 1810 | 0.100 |
Why?
| | Forced Expiratory Volume | 1 | 2014 | 448 | 0.100 |
Why?
| | Academies and Institutes | 1 | 2013 | 58 | 0.100 |
Why?
| | Glucagon-Like Peptides | 1 | 2014 | 70 | 0.100 |
Why?
| | Administration, Inhalation | 1 | 2014 | 570 | 0.100 |
Why?
| | Interprofessional Relations | 1 | 2015 | 275 | 0.090 |
Why?
| | Drug Administration Schedule | 1 | 2014 | 779 | 0.090 |
Why?
| | Behavior | 1 | 2013 | 90 | 0.090 |
Why?
| | Self Report | 1 | 2017 | 869 | 0.090 |
Why?
| | Organizational Objectives | 1 | 2012 | 66 | 0.090 |
Why?
| | Professional Competence | 1 | 2012 | 93 | 0.090 |
Why?
| | Recombinant Fusion Proteins | 1 | 2014 | 667 | 0.090 |
Why?
| | Drug Therapy, Combination | 1 | 2014 | 1044 | 0.090 |
Why?
| | Employment | 1 | 2012 | 184 | 0.080 |
Why?
| | Interdisciplinary Communication | 1 | 2012 | 200 | 0.080 |
Why?
| | Comorbidity | 1 | 2015 | 1652 | 0.080 |
Why?
| | Life Style | 1 | 2013 | 481 | 0.080 |
Why?
| | Qualitative Research | 3 | 2025 | 1668 | 0.080 |
Why?
| | Health Planning Guidelines | 1 | 2009 | 24 | 0.070 |
Why?
| | Clinical Trials as Topic | 1 | 2014 | 1056 | 0.070 |
Why?
| | Retrospective Studies | 2 | 2019 | 17149 | 0.070 |
Why?
| | Cooperative Behavior | 1 | 2012 | 464 | 0.070 |
Why?
| | Learning | 1 | 2013 | 448 | 0.070 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2015 | 1742 | 0.070 |
Why?
| | Peptides | 1 | 2014 | 989 | 0.070 |
Why?
| | Physician's Role | 1 | 2009 | 221 | 0.060 |
Why?
| | Patient Education as Topic | 1 | 2012 | 771 | 0.060 |
Why?
| | Delivery of Health Care | 1 | 2013 | 944 | 0.060 |
Why?
| | Blood Pressure | 1 | 2012 | 1766 | 0.060 |
Why?
| | Gastric Inhibitory Polypeptide | 1 | 2022 | 13 | 0.050 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2025 | 299 | 0.040 |
Why?
| | Time Factors | 1 | 2013 | 7140 | 0.040 |
Why?
| | Biomarkers | 1 | 2012 | 4261 | 0.040 |
Why?
| | Anecdotes as Topic | 1 | 2020 | 7 | 0.040 |
Why?
| | Surveys and Questionnaires | 2 | 2025 | 6041 | 0.040 |
Why?
| | Competitive Behavior | 1 | 2020 | 44 | 0.040 |
Why?
| | Adult | 1 | 2022 | 40489 | 0.040 |
Why?
| | Benchmarking | 1 | 2019 | 189 | 0.030 |
Why?
| | Self Concept | 1 | 2020 | 256 | 0.030 |
Why?
| | Focus Groups | 1 | 2020 | 566 | 0.030 |
Why?
| | Accreditation | 1 | 2017 | 101 | 0.030 |
Why?
| | Interpersonal Relations | 1 | 2020 | 399 | 0.030 |
Why?
| | Research Report | 1 | 2015 | 86 | 0.030 |
Why?
| | Emotions | 1 | 2020 | 578 | 0.030 |
Why?
| | Faculty | 1 | 2015 | 153 | 0.030 |
Why?
| | Community Networks | 1 | 2013 | 57 | 0.020 |
Why?
| | Pharmacy Service, Hospital | 1 | 2013 | 81 | 0.020 |
Why?
| | Data Collection | 1 | 2012 | 635 | 0.020 |
Why?
| | Internship and Residency | 1 | 2017 | 1262 | 0.020 |
Why?
| | Communication | 1 | 2012 | 972 | 0.010 |
Why?
| | Animals | 1 | 2025 | 37948 | 0.010 |
Why?
| | Male | 1 | 2020 | 72431 | 0.010 |
Why?
| | Female | 1 | 2020 | 78304 | 0.010 |
Why?
|
|
Nuffer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|